DaShenLin Pharmaceutical Group Co., Ltd. Stock price

Equities

603233

CNE100002RG2

Drug Retailers

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
21.11 CNY +0.19% Intraday chart for DaShenLin Pharmaceutical Group Co., Ltd. -2.49% -15.22%
Sales 2023 * 24.72B 3.42B Sales 2024 * 30.75B 4.25B Capitalization 24B 3.32B
Net income 2023 * 1.31B 181M Net income 2024 * 1.63B 226M EV / Sales 2023 * 0.92 x
Net cash position 2023 * 1.37B 189M Net cash position 2024 * 1.72B 238M EV / Sales 2024 * 0.72 x
P/E ratio 2023 *
18.3 x
P/E ratio 2024 *
14.8 x
Employees 39,499
Yield 2023 *
2.75%
Yield 2024 *
3.32%
Free-Float 33.36%
More Fundamentals * Assessed data
Dynamic Chart
Dashenlin Pharmaceutical to Buy Back Up to 200 Million Yuan Shares MT
Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares MT
DaShenLin Pharmaceutical Group Co., Ltd. cancelled the transaction announced on January 19, 2023 CI
Dashenlin Pharmaceutical to Boost Stake in Local Pharmacy Chain to 66% For 30 Million Yuan MT
DaShenLin Pharmaceutical Group Co., Ltd. agreed to acquire 15% stake in Chongqing Wanjiayan Pharmacy Chain Co., Ltd from Chongqing Wanjiayan Health Industry Group Co., Ltd. and Bai Run for CNY 30 million. CI
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Dashenlin Pharmaceutical Unit Acquires Land for 1.20 Billion Yuan; Shares Jump 4% MT
DaShenLin Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 3.025 billion in funding CI
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Beijing Mulls Banning Internet Healthcare Firms From Selling Drugs Online MT
UBS Adjusts Dashenlin Pharmaceutical's Price Target to 40 Yuan From 73.5 Yuan, Keeps at Buy MT
More news
1 day-1.17%
1 week-2.68%
Current month-11.43%
1 month-11.77%
3 months-16.39%
6 months-15.89%
Current year-15.38%
More quotes
1 week
21.04
Extreme 21.04
21.85
1 month
21.03
Extreme 21.03
23.96
Current year
20.94
Extreme 20.94
27.10
1 year
20.94
Extreme 20.94
32.25
3 years
15.90
Extreme 15.9028
51.78
5 years
15.90
Extreme 15.9028
61.63
10 years
11.00
Extreme 11.0028
61.63
More quotes
Managers TitleAgeSince
Chief Executive Officer 42 -
Director of Finance/CFO 42 18-05-09
Chairman 46 15-05-27
Members of the board TitleAgeSince
Director/Board Member 61 16-08-07
Founder 57 99-02-11
Chairman 46 15-05-27
More insiders
Date Price Change Volume
24-03-27 21.11 +0.19% 7 593 993
24-03-27 21.07 -1.17% 4,980,531
24-03-26 21.32 +0.76% 4,445,482
24-03-25 21.16 -0.70% 4,702,411
24-03-22 21.31 -2.11% 5,948,041

End-of-day quote Shanghai S.E., March 26, 2024

More quotes
DaShenLin Pharmaceutical Group Co., Ltd. is a China-based company principally engaged in the pharmaceutical retailing business. The Company's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The Company mainly conducts its business within domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
21.07 CNY
Average target price
33.76 CNY
Spread / Average Target
+60.24%
Consensus
  1. Stock
  2. Equities
  3. Stock DaShenLin Pharmaceutical Group Co., Ltd. - Shanghai S.E.